Multiple sclerosis arises from immune-mediated attack on myelin and oligodendrocytes in the central nervous system, causing demyelination and axonal loss. Stem-cell strategies target both immune dysregulation and repair: placental mesenchymal stem cells are studied for their capacity to calm autoreactive immune cells and secrete neuroprotective factors, while neurogenic cells are explored for remyelination and axonal support. Preclinical work suggests stem cells migrate toward lesions and release anti-inflammatory mediators. Trials have enrolled relapsing-remitting and progressive forms, but the mechanism of any benefit is incompletely characterised, and no approach yet reverses established disability or halts long-term progression in humans.
Ninety-two registered trials and 14 recruiting studies investigate stem-cell therapy in MS, across Europe, Asia and North America. Small series describe reduced relapse rates or stable disability scores; some show fewer inflammatory (gadolinium-enhancing) brain lesions over 6–12 months. MS is naturally variable, so separating stem-cell effects from disease fluctuation or concurrent disease-modifying drugs is difficult without controls. No trial has shown stem cells to be superior to established MS therapies; long-term data are sparse.
Indicative European costs are roughly €4,500–€7,500 per course, reflecting manufacturing, sterility testing, and often multiple doses. MS patients usually need MRI before and after, and intrathecal (spinal) delivery may require hospitalisation, raising the total. Established MS disease-modifying therapies cost roughly €800–€3,000 monthly via insurance and are proven — the stem-cell figure is indicative and unproven.
Cell therapy for Multiple Sclerosis is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Multiple Sclerosis programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
← Back to Multiple Sclerosis overview · Multiple Sclerosis cost →
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估